AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Identification of Arginine Deiminase Gene Therapy for Disordered Proteins
Technology Benefits
Decreases tau levels, Metabolizes arginine, Does not increase nitric oxide or polyamines
Detailed Technology Description
Our inventorΓÇÖs have successfully mammalianized, cloned, and expressed arginine deiminase (ADI) to deplete arginine without increasing either nitric oxide or polyamines. When overexpressed in the brain of tau transgenic mice, ADI significantly decreased tau pathology. Additionally, ADI reduced tau levels in cells that overexpress tau. This novel gene therapy by ADI may serve as a therapeutictarget in reducing aggregation prone proteins such as tau, thus leading to a promising new treatment for age-associated neurodegenerative diseases.
Country/Region
USA
For more information, please click Here
